摘要
目的探讨安博维联合黄葵胶囊治疗慢性肾炎(CGN)患者的临床效果。方法随机抽取64例患有慢性肾炎蛋白尿的患者,将其分为A、B两组,平均每组32例,A组给予黄葵胶囊治疗,B组在A组治疗的基础上给予安博维。疗程为1年,观察两组的临床效果、治疗前后蛋白尿、血肌酐(Scr)、并发症以及不良反应情况。结果经1年的治疗,A组有效率87.5%,B组有效率为100%,B组患者的临床疗效明显好于A组,差异有统计学意义(P<0.05);B组患者治疗前后的蛋白尿量改善幅度明显大于A组患者,差异有统计学意义(P<0.05);B组患者在治疗前后的Scr变化幅度小于A组患者,差异无统计学意义(P>0.05);两组患者在治疗的过程中,均未出现比较严重的不良反应和并发症,肝肾功能均无恶化。结论安博维联合黄葵胶囊对CGN蛋白尿的疗效显著。
Objective To explore the clinical efficacy of the treatment of Aprovel combined with Huangkui Capsule on chronic nephritis patients with proteinuria .Methods 64 cases of patients suffering from chronic nephritis with proteinuria Were randomly divided into two groups（A group and B group）,each group had 32 cases. A group took Huangkui Capsule treatment ,B group took Aprovel on the basis of the group A. After one year treatment, observed the proteinuria, serum creatinine, blood pressure, complications and and adverse reactions. Results After one year of treatment, the effective rate was 87.5% in A group, the effective rate of B group was 100%. Clinical group B was significantly better than in group A, the difference was statistically significant （P 〈0.05）. After treatment, the improve of proteinuria in B group were better than A group.（P〈0.05）. The serum creatinine of B group were better than A group（P〉0.05）. Systolic and diastolic blood pressure of the two groups of patients with significant improvement after treatment （P 〈0.05）.And the B group were better than A froup, the difference was significant （P 〈0.05）. The two groups of patients were no serious adverse reactions and complications, liver and kidney function in the process of treatment, there was no deterioration. Conclusion The Aprovel combined with Huangkui Capsule has a better clinical efficacy on chronic nephritis patients with proteinuria .It is worthy being spread.
出处
《湖南中医药大学学报》
CAS
2013年第12期19-20,共2页
Journal of Hunan University of Chinese Medicine
